iCAD Showcases New Portfolio of Advanced Image Analysis and Workflow Solutions for Early Detection of Cancer at the 2008 RSNA

NASHUA, N.H.--([ BUSINESS WIRE ])--iCAD, Inc. (Nasdaq: ICAD), an industry-leading provider of advanced image analysis and workflow solutions for the early identification of cancer, today unveiled its latest innovations at the 94th annual meeting of the Radiological Society of North America (RSNA) in Chicago, from November 30 through December 5, 2008.

"This year we have expanded our portfolio of image analysis and workflow solutions beyond mammography CAD into the imaging modalities of Computed Tomography (CT) and Magnetic Resonance Imaging (MRI) extending our reach and broadening our leadership position," said Ken Ferry, president and CEO of iCAD. "This enables us to help clinicians find the most prevalent cancers including breast, colon and prostate, earlier, faster and with greater confidence."

At this year's RSNA, iCAD will launch several new CAD analysis and clinical decision support solutions that work in combination with CT and MRI imaging modalities.

SpectraLook™ and VividLook™ use innovative algorithms that generate colorized MRI images and enhancement curves on a pixel-by-pixel basis, providing radiologists with timely and efficient contrast kinetic assessment of lesions in the breast and prostate;
CADvue™ is a complete MRI image review, analysis and BI-RADS^®compatible reporting solution providing contrast enhancement curves, dynamic 3D images and quantification of key lesion parameters. CADvue's automation of critical manual steps provides a significant reduction in the time required to generate curves and streamlines radiologist's work flow and diagnosis.
VeraLook™ is a revolutionary CAD solution for virtual colonoscopy (CTC) designed to aid radiologists in the detection of polyps during their review of CTC exams. Early clinical evidence suggests that CAD for CTC will enhance radiologist effectiveness in interpreting CTC studies.*

iCAD will also demonstrate elements of their next generation SecondLook Digital CAD solution currently under development. Advances shown will include performance improvements, software enhancements, and new "lesion metrics" that provide insight into CAD's decision making process.

Additional company highlights at the RSNA include iCAD's industry-leading SecondLook Digital CAD system, which offers unique compatibility with industry leading Full-Field Digital Mammography (FFDM) solutions – both Digital Radiography (DR) and Computed Radiography (CR). Highlighted will be the SecondLook Digital CAD for Fujifilm CR systems, which is the first and only CAD solution to receive FDA approval and is already installed in numerous sites across the globe. iCAD will also be demonstrating new customized CAD solutions for Agfa CR**, Sectra**, Philips CR** and Planmed** digital mammography systems. SecondLook Digital CAD will broaden and strengthen these solutions by providing enhanced detection and workflow capabilities, and will deliver powerful performance improvements increasing the radiologist's confidence.

iCAD will also demonstrate its state-of-the-art film digitizing solution, TotalLook MammoAdvantage^TM(TLMA) that is an integral part of the digital mammography workflow. iCAD's second generation mammography-specific digitizer, TLMA offers improved image quality, enhanced image customization options and workflow efficiency benefits to centers moving from analog to digital mammography. TMLA's unique software offers configurable image resolution settings that enable the digitized and newly acquired digital images to be displayed at the same size. The software provides flexible DICOM connectivity solutions for seamless integration with leading review workstations, PACS and RIS systems and its specialized image compression techniques reduce file sizes up to 80 percent, minimizing long-term storage requirements.

"Radiologists are facing increasing volumes in both the number of studies they need to review as well as the number of images in each study with MRI and CT. Automation of time-consuming manual processes and advanced analysis of these images will play a critical role in improving the imaging workflow for the radiologist and increasing their diagnostic confidence" added Ferry. "As facilities look to become more effective and efficient in managing the flow of their patients and providing enhanced patient care, iCAD's innovative image analysis and workflow solutions have proven their clinical value and make us an ideal choice for imaging departments and centers."

All of these products will be featured at the iCAD booth, #6250, located at McCormick Place, Hall A.

* Investigational Device. Limited by Federal Law to Investigational Use.

**Only available internationally

About iCAD, Inc.

iCAD, Inc. is an industry-leading provider of advanced image analysis and workflow solutions that enable healthcare professionals to better serve patients by identifying pathologies and pinpointing cancer earlier. iCAD offers a comprehensive range of high-performance, upgradeable Computer-Aided Detection (CAD) systems and workflow solutions for mammography (film-based, digital radiography (DR) and computed radiography (CR), Magnetic Resonance Imaging (MRI), and Computed Tomography (CT). iCAD's solutions aid in the early detection of the most prevalent cancers including breast, colon, prostate and in the future, lung cancer. Today iCAD has more than 3,100 systems in use in mammography centers worldwide. For more information, call (877) iCAD now or visit [ www.icadmed.com ].

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995

Certain statements contained in this News Release, including but not limited to, statements about the Company's confidence or strategies or expectations about revenues, results of operations, timing of regulatory approval of products or market opportunities, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited to, the risks of uncertainty of patent protection, the impact of supply and manufacturing constraints or difficulties, product market acceptance, possible technological obsolescence, increased competition, customer concentration and other risks detailed in the Company's filings with the Securities and Exchange Commission. The words "believe", "demonstrate", "intend", "expect", "estimate", "anticipate", "likely", and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release.

N@N

iCAD Showcases New Portfolio of Advanced Image Analysis and Workflow Solutions for Early Detection of Cancer at the 2008 RSNA